Drug Trial Radar · NCT00264303
CUTE (Chronic Urticaria Treatment Evaluation)
Last checked: Nov 20, 2026Latest source record: Aug 31, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
886
Actual
Start
Dec 2005
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Dec 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment
Conditions
- Chronic Idiopathic Urticaria
Interventions
LevocetirizineDrug
5mg oral capsules, once daily, 4 week duration
DesloratadineDrug
5mg oral capsules, once daily, 4 week duration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Pruritus Severity Score Over the First Week of TreatmentTime frame: over the first week of treatment
Locations
80 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Bruges, Belgium
Site not named
Brussels, Belgium
Site not named
Liège, Belgium
Site not named
Merksem, Belgium
Site not named
Sint-Niklaas, Belgium
Site not named
Woluwe-St-Lamb, Belgium
Site not named
Bernay, France
Site not named
Besançon, France
Site not named
Hyères, France
Site not named
Les Milles, France
Site not named
Marseille, France
Site not named
Montpellier, France
Site not named
Nancy, France
Site not named
Nantes, France
Site not named
Nice, France
Site not named
Nîmes, France
Site not named
Paris, France
Site not named
Poitiers, France
Site not named
Quimper, France
Site not named
Saint-Mandé, France
Site not named
Troyes, France
Site not named
Valence, France
Site not named
Villejuif, France
Site not named
Augsburg, Germany
Site not named
Berlin, Germany
Site not named
Cologne, Germany
Site not named
Dresden, Germany
Site not named
Düsseldorf, Germany
Site not named
Erlangen, Germany
Site not named
Göttingen, Germany
Site not named
Hamburg, Germany
Site not named
Hanover, Germany
Site not named
Leipzig, Germany
Site not named
Mahlow, Germany
Site not named
Mainz, Germany
Site not named
München, Germany
Site not named
Viersen, Germany
Site not named
Caserta, Italy
Site not named
Catania, Italy
Site not named
Cesena, Italy
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.